Novartis AG Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used
Novartis AG (NVS) reported Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used of $5.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed · last filed 2026-02-04
- Novartis AG expense relating to shortterm leases for which recognition exemption has been used for the quarter ending 2019-06-30 was $2.00M.
| Period end | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 3 month | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 6 month | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.00M 20-F · filed 2026-02-04 | |||
| 2024-12-31 | $7.00M 20-F · filed 2026-02-04 | |||
| 2023-12-31 | $5.00M 20-F · filed 2026-02-04 | |||
| 2022-12-31 | $3.00M 20-F · filed 2025-01-31 | |||
| 2021-12-31 | $6.00M 20-F · filed 2024-01-31 | |||
| 2020-12-31 | $4.00M 20-F/A · filed 2023-05-15 | |||
| 2019-12-31 | $7.00M 20-F · filed 2022-02-02 | |||
| 2019-06-30 | $2.00M 6-K · filed 2019-07-18 | $4.00M 6-K · filed 2019-07-18 | ||
| 2019-01-01 | $30.00M 6-K · filed 2019-07-18 | |||
| 2018-12-31 | $30.00M 20-F · filed 2020-01-29 |